Reese Randle to Peritoneal Neoplasms
This is a "connection" page, showing publications Reese Randle has written about Peritoneal Neoplasms.
Connection Strength
1.918
-
Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, Shen P, Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015 May; 111(6):740-5.
Score: 0.386
-
Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015 May; 22(5):1634-8.
Score: 0.376
-
Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014 May; 21(5):1474-9.
Score: 0.352
-
Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013 Jun; 79(6):620-4.
Score: 0.346
-
Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015 Apr; 22(4):1274-9.
Score: 0.095
-
Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015 May; 22(5):1645-50.
Score: 0.094
-
Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Dec; 21(13):4226-31.
Score: 0.093
-
Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Mar; 21(3):868-74.
Score: 0.089
-
Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, Levine EA. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol. 2013 Nov; 20(12):3899-904.
Score: 0.087